Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography

Launched by EGE UNIVERSITY · Jun 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called low molecular weight heparin (LMWH) to help prevent blood clots in patients who have just had surgery to remove part of their lung due to cancer. The researchers want to find out if using LMWH after surgery is necessary and effective. To do this, they will take blood samples from participants at different times: before surgery, on the first day after surgery, and again three days after starting the LMWH treatment. They will analyze these samples using a special test called thromboelastography to see how well the blood is clotting.

To be eligible for this trial, participants must be adults aged 65 to 74 who have recently undergone a lobectomy (a type of lung surgery) for lung cancer. However, individuals with bleeding disorders or those who have received certain blood-thinning treatments before surgery cannot participate. If you decide to join this trial, you can expect to provide blood samples at specific times, and this will help researchers learn more about how to prevent blood clots in patients after surgery. Your participation could contribute to important findings that may benefit future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who underwent lobectomy with thoracotomy or videothoracoscopy (VATS) due to malignancy (primary or secondary lung cancer)
• Exclusion Criteria:
• • Patients with a known diagnosis of bleeding or coagulation disorders
• • Patients receiving anticoagulant and antiplatelet therapy in the preoperative period
• • Patients who developed perioperative bleeding and therefore underwent perioperative blood and blood product replacement